Hemophilia B is rare in females and only a few cases have been reported. In this report, we describe a girl with a clinically severe course of hemophilia B but with a normal 46,XX karyotype. She had no signs of Turner’s syndrome or any other dysmorphic features. She was demonstrated to have moderately decreased factor IX levels (factor IX:C, 1.5 units/dl; factor IX:Ag, 2.2 units/dl). Her father and paternal uncle were also found to be deficient in factor IX and her mother seemed to carry a factor IX gene mutation with intermediate factor IX:C and factor IX:Ag levels (factor IX:C, 46 units/dl; factor IX:Ag, 39 units/dl). The maternal grandmother also showed mildly decreased factor IX:C and factor IX:Ag levels (factor IX:C 41 units/dl; factor IX:Ag 32 units/dl), further confirming the mother’s carrier status, which was indirectly confirmed by DNA segregation analysis using the polymorphic markers of the factor IX gene, as none of her other family members were found to be deficient in factor IX. However, the Dde I polymorphic marker of the factor IX gene for which the mother was informative showed the inheritance of a ‘369-bp’ allele in the mother, which was different from the ‘319-bp’ allele found in all of her 3 brothers who had normal levels of factor IX. Intermediate levels of factor IX in the mother and the maternal grandmother, severe deficiency of factor IX in the child and the polymorphic allele different from that of the normal subjects in the family are all consistent with a homozygous or double-heterozygous condition in this child.

Ingerslev J, Schwartz M, Lamm LU, Kruse T, Bukh A, Stenbjerg S: Female haemophilia A in a family with seeming extreme bidirectional lyonization tendency: Abnormal premature X-chromosome inactivation? Clin Genet 1989;35:41–48.
Wadelius C, Lindstedt M, Pigg M, Egberg N, Petterson U, Anvret M: Hemophilia B in a 46,XX female probably caused by non-random X inactivation. Clin Genet 1993;43:1–4.
Panarello C, Acquila M, Caprino D, Gimelli G, Pecorara M, Mori PG: Concomitant Turner syndrome and hemophilia A in a female with an idic(X)(p11) heterozygous at locus DXS52, Cytogenet Cell Genet 1992;59:241–242.
Schroder W, Poetsch M, Gazda H, Werner W, Reichelt T, Knoll W, Rokicka-Milewska R, Zieleniewska B, Herrmann FH: A de novo translocation 46,Xt(X;15) causing haemophilia B in a girl: A case report. Br J Haematol 1998;100:750–757.
Mori PG, Pasino M, Vadala CR, Bisogni MC, Tonini GP, Scarabicchi S: Hemophilia ‘A’ in a 46,X,i(Xq) female. Br J Haematol 1979;43:143–147.
Lusher JM, McMillan CW: Severe factor VIII and factor IX deficiency in females. Am J Med 1978;65:637–648.
Kling S, Coffey AJ, Ljung R, Sjorin E, Nilsson IM, Holmberg L, Giannelli F: Moderate haemophilia B in a female carrier caused by preferential inactivation of the paternal X chromosome. Eur J Haematol 1991;17:257–261.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, ed 2. New York, Cold Spring Harbor Laboratory Press, 1989.
Peake IR, Lillicrap DP, Boulyjenkov V, Briet E, Chan V, Ginter EK, Kraus EM, Ljung R, Mannucci PM, Nicolaides K, et al: Report of a joint WHO/WFH meeting on the control of haemophilia: Carrier detection and prenatal diagnosis. Blood Coagul Fibrinolysis 1993;4:313–344.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.